PD-217,014
Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number |
|
| PubChem CID |
|
| ChemSpider |
|
| UNII |
|
| Chemical and physical data | |
| Formula | C10H17NO2 |
| Molar mass | 183.251 g·mol−1 |
| 3D model (JSmol) |
|
| |
InChI
| |
PD-217,014 is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2). It was developed as a potentially more potent successor to gabapentin and pregabalin, along with several other analogues such as atagabalin and 4-methylpregabalin, but while PD-217,014 produces visceral analgesic effects in animal studies with higher potency and efficacy than gabapentin, it was not developed further for clinical use because of its comparatively more complex synthesis, compared to other related analogues.[1]
References
- ^ Ohashi K, Kawai M, Ninomiya N, Taylor C, Kurebayashi Y (2008). "Effect of a new alpha 2 delta ligand PD-217014 on visceral hypersensitivity induced by 2,4,6-trinitrobenzene sulfonic acid in rats". Pharmacology. 81 (2): 144–50. doi:10.1159/000110737. PMID 17989503. S2CID 84708161.
- v
- t
- e
modulators
| Calcium blockers |
|
|---|---|
| Sodium blockers |
|
| Potassium openers |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This analgesic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
